SCN Signs Strategic, Regional Agreement for Coldizin and Immulina in South Eastern Europe

Scandinavian Clinical Nutrition AB (SCN) has entered into an exclusive, strategic distribution and supply agreement for the patented products Coldizin and Immulina in South Eastern Europe with a leading company in the Greek health market, Alapis S.A.

Under the agreement, Alapis S.A. will exclusively market and distribute Coldizin and Immulina each in eight countries: Greece, Serbia, Bulgaria, Romania, Croatia, Slovenia, Montenegro, Bosnia-Herzegovina, FYRM and Albania. The initial focus will be the launch of both SCN products in Greece and Serbia during Q3 2009, with the other markets to follow successively thereafter.

Alapis is headquartered in Athens, Greece and employs over 2’900 employees, with a turnover exceeding EUR 1.1 billion in 2008. The human healthcare division is the company’s largest business unit, including pharmaceuticals, medical devices, diagnostics and OTC. The remaining strategic business units cover veterinary pharmaceuticals and pet accessories, cosmetics and detergents.

“We have been impressed by the unique and scientifically documented product propositions SCN has presented to us and are intent on growing our organic business further with these products in all our key markets,” says Nickolas Korbis, Executive Member of the Board of Directors and Senior Director of Business Development at Alapis.

“We are proud to achieve this milestone agreement”, says Danilo Copiz, VP Sales at SCN, “because Alapis is able to launch our products throughout a large regional area and SCN is poised to benefit from the penetration Alapis S.A. enjoys on its main markets today.”

With this exclusive distribution agreement, Coldizin has distribution agreements in place on 20 markets world-wide, while Immulina is on 12 markets. Under the agreement, Alapis S.A. will be responsible for product marketing and promotion, as well as local regulatory issues, supported by the expertise from SCN.